Your browser doesn't support javascript.
loading
Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Schubert, Maria-Luisa; Dietrich, Sascha; Stilgenbauer, Stephan; Schmitt, Anita; Pavel, Petra; Kunz, Alexander; Bondong, Andrea; Wegner, Mandy; Stadtherr, Peter; Jung, Susanne; Ho, Anthony D; Müller-Tidow, Carsten; Schmitt, Michael; Dreger, Peter.
Afiliação
  • Schubert ML; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. Electronic address: maria-luisa.schubert@med.uni-heidelberg.de.
  • Dietrich S; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Centre for Tumor Diseases (NCT), Heidelberg, Germany.
  • Stilgenbauer S; Department of Internal Medicine III, Ulm University Medical Center, Ulm, Germany.; Department of Internal Medicine I, Saarland University Medical Center, Homburg, Germany.
  • Schmitt A; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Pavel P; Stem Cell Laboratory, Institute for Clinical Transfusion Medicine and Cell Therapy (IKTZ), German Red Cross Blood Service Baden-Württemberg-Hessen, Heidelberg, Germany.
  • Kunz A; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Bondong A; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Wegner M; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Stadtherr P; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Jung S; Diakonissenkrankenhaus und Paulinenhilfe gGmbH, Diakonie-Klinikum, Stuttgart, Germany.
  • Ho AD; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Centre for Tumor Diseases (NCT), Heidelberg, Germany.
  • Müller-Tidow C; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Centre for Tumor Diseases (NCT), Heidelberg, Germany.
  • Schmitt M; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Centre for Tumor Diseases (NCT), Heidelberg, Germany.
  • Dreger P; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Centre for Tumor Diseases (NCT), Heidelberg, Germany.
Biol Blood Marrow Transplant ; 26(9): 1575-1580, 2020 09.
Article em En | MEDLINE | ID: mdl-32422254
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Receptores de Antígenos Quiméricos Limite: Adult / Humans Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Receptores de Antígenos Quiméricos Limite: Adult / Humans Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2020 Tipo de documento: Article